logo-loader
viewImmuPharma PLC

2019 Annual General Meeting

/**/ p{margin-top:0cm;margin-right:0cm;margin-bottom:7.5pt;margin-left:0cm;line-height:13.5pt;font-size:8.5pt;font-family:"Times New Roman","serif";color:#666666;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .ag{size:612.0pt 792.0pt;margin:72.0pt 90.0pt 72.0pt 90.0pt;}div.ag{}p.bg{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}span.be{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.bh{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify}span.bc{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.bi{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align:justify}span.ba{font-size: 11.0pt;font-family:"Calibri","sans-serif"}p.bj{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext; font-weight: bold; text-align: center}span.ay{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} p.bk{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext; text-align: center}p.bl{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;}span.au{font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight:normal}p.o,li.o,div.o{margin-right:0cm;margin-left:0cm;line-height:normal;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;}span.p{}table.bm{width:606.25pt;margin-left:-10.8pt;border-collapse:collapse}td.ai{width:595.45pt;padding:0cm 5.4pt 0cm 5.4pt}span.at{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}table.bn{width:18.0cm;border-collapse:collapse} td.ar{width:294.0pt;padding:0cm 5.4pt 0cm 5.4pt}a.as{font-weight: bold}td.aq{width:194.7pt;padding:0cm 5.4pt 0cm 5.4pt}span.ap{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}span.ao{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}span.bo{color:blue;font-size:11.0pt;font-family:"Calibri","sans-serif"; color:windowtext;text-decoration:none}p.bp{margin:0cm;margin-bottom:.0001pt;line-height:normal;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-right:-5.4pt;text-align:justify}td.al{width:150.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.ak{border:none;padding:0cm 0cm 0cm 0cm} /**/
RNS Number : 6908D
Immupharma PLC
27 June 2019
 

 

 

 

                                                                                                                                                                      27 JUNE 2019

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

2019 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

-Ends-

 

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGMUBOURKVANUAR

Quick facts: ImmuPharma PLC

Price: 22

Market: AIM
Market Cap: £36.82 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma's Tim McCarthy details Lupuzor licensing deal with Avion...

ImmuPharma PLC's (LON:IMM) chairman Tim McCarthy caught up with Proactive's Andrew Scott to talk through the recently announced licensing deal worth almost US$100mln for Lupuzor -  its treatment for the autoimmune disease lupus. US speciality drugs group Avion Pharmaceuticals will fund...

3 days, 7 hours ago